Wells Fargo’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-46,866
| Closed | -$613K | – | 7184 |
|
|
2025
Q4 | $613K | Buy |
46,866
+18,720
| +67% | +$224K | ﹤0.01% | 4333 |
|
|
2025
Q3 | $205K | Buy |
28,146
+714
| +3% | +$4.83K | ﹤0.01% | 4920 |
|
|
2025
Q2 | $147K | Buy |
27,432
+3,356
| +14% | +$16.3K | ﹤0.01% | 4948 |
|
|
2025
Q1 | $129K | Buy |
24,076
+507
| +2% | +$3.55K | ﹤0.01% | 4965 |
|
|
2024
Q4 | $211K | Buy |
23,569
+7,563
| +47% | +$80.3K | ﹤0.01% | 4766 |
|
|
2024
Q3 | $176K | Sell |
16,006
-333
| -2% | -$3.7K | ﹤0.01% | 4668 |
|
|
2024
Q2 | $149K | Sell |
16,339
-700
| -4% | -$6.83K | ﹤0.01% | 4700 |
|
|
2024
Q1 | $240K | Sell |
17,039
-9,841
| -37% | -$123K | ﹤0.01% | 4360 |
|
|
2023
Q4 | $206K | Buy |
26,880
+21,455
| +395% | +$119K | ﹤0.01% | 4446 |
|
|
2023
Q3 | $40.5K | Sell |
5,425
-5,111
| -49% | -$43.6K | ﹤0.01% | 5290 |
|
|
2023
Q2 | $87.8K | Buy |
10,536
+10,374
| +6,404% | +$120K | ﹤0.01% | 5124 |
|
|
2023
Q1 | $2.15K | Buy |
162
+75
| +86% | +$1.01K | ﹤0.01% | 6212 |
|
|
2022
Q4 | $1.29K | Buy |
87
+27
| +45% | +$278 | ﹤0.01% | 6107 |
|
|
2022
Q3 | $1K | Sell |
60
-4
| -6% | -$27 | ﹤0.01% | 6271 |
|
|
2022
Q2 | $0 | Buy |
64
+6
| +10% | +$27 | ﹤0.01% | 6778 |
|
|
2022
Q1 | $0 | Hold |
58
| – | – | ﹤0.01% | 7027 |
|
|
2021
Q4 | $0 | Buy |
58
+1
| +2% | +$7 | ﹤0.01% | 7196 |
|
|
2021
Q3 | $1K | Sell |
57
-52
| -48% | -$498 | ﹤0.01% | 6652 |
|
|
2021
Q2 | $1K | Sell |
109
-956
| -90% | -$12.4K | ﹤0.01% | 6619 |
|
|
2021
Q1 | $18K | Sell |
1,065
-16,098
| -94% | -$291K | ﹤0.01% | 6185 |
|
|
2020
Q4 | $220K | Sell |
17,163
-4,430
| -21% | -$79K | ﹤0.01% | 5031 |
|
|
2020
Q3 | $802K | Buy |
21,593
+15,931
| +281% | +$631K | ﹤0.01% | 4022 |
|
|
2020
Q2 | $219K | Buy |
5,662
+5,645
| +33,206% | +$201K | ﹤0.01% | 4857 |
|
|
2020
Q1 | $0 | Buy |
+17
| New | +$527 | ﹤0.01% | 6180 |
|
|
2019
Q4 | – | Sell |
-2,748
| Closed | -$89K | – | 6341 |
|
|
2019
Q3 | $89K | Buy |
2,748
+1,045
| +61% | +$41.3K | ﹤0.01% | 5370 |
|
|
2019
Q2 | $82K | Buy |
+1,703
| New | +$77.2K | ﹤0.01% | 5385 |
|
|
2016
Q2 | – | Sell |
-5
| Closed | -$1K | – | 6086 |
|
|
2016
Q1 | $1K | Buy |
+5
| New | +$1.72K | ﹤0.01% | 6079 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6209 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6189 |
|
Wells Fargo's ATXS Position: Q1 2026 in Review
Wells Fargo sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 46,866 shares — an estimated $613K sold.
Wells Fargo first reported a position in ATXS in Q1 2016 and held it in 27 quarters. The position peaked at $802K in Q3 2020. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Wells Fargo reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Wells Fargo sold 46,866 Astria Therapeutics shares in Q1 2026, an estimated $613K.
- Wells Fargo first reported a position in Astria Therapeutics in Q1 2016 and held it in 27 quarters.
- Wells Fargo's Astria Therapeutics position peaked at $802K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.